Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Income (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Non Operating Income data on record, last reported at $910000.0 in Q2 2025.

  • For Q2 2025, Non Operating Income rose 550.5% year-over-year to $910000.0; the TTM value through Jun 2025 reached $5.4 million, down 62.32%, while the annual FY2025 figure was $9.7 million, 27.43% up from the prior year.
  • Non Operating Income reached $910000.0 in Q2 2025 per TNGX's latest filing, down from $1.1 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $8.7 million in Q4 2023 and bottomed at -$289000.0 in Q4 2021.
  • Average Non Operating Income over 5 years is $1.4 million, with a median of $1.1 million recorded in 2023.
  • Peak YoY movement for Non Operating Income: plummeted 1350.0% in 2021, then soared 2876.0% in 2022.
  • A 5-year view of Non Operating Income shows it stood at -$289000.0 in 2021, then skyrocketed by 639.1% to $1.6 million in 2022, then soared by 457.12% to $8.7 million in 2023, then tumbled by 83.0% to $1.5 million in 2024, then plummeted by 38.35% to $910000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were $910000.0 in Q2 2025, $1.1 million in Q1 2025, and $1.5 million in Q4 2024.